FTSE MIB
30.403,90 +282,13 (+0,94%) Dow Jones
36.247,87 +130,49 (+0,36%) Nasdaq
14.403,97 +63,98 (+0,45%) Nikkei 225
32.307,86 -550,45 (-1,68%) Petrolio
71,26 +1,92 (+2,77%) Bitcoin EUR
40.630,11 -381,58 (-0,93%)
Oryzon Genomics S.A. (0RDB.L)
- GlobeNewswire
ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company presented an update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the 36th European College of Neu
- GlobeNewswire
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
Two collaborative projects with public research centers with a global budget of 2.3 million eurosOryzon to receive up to 1.4 million eurosFocused on the discovery and validation of novel biomarkers and epigenetic targets for the treatment of neuronal pathologies MADRID, Spain and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medica
- GlobeNewswire
ORYZON to Provide Corporate Progress Updates at Several Events in October
East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023)Investor Access 2023 EventJefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2nd Healthcare Opportunities Conference ESMO (European Society for Medical Oncology) 2023 congress MADRID, Spain and BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases
